Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Glioma candidate pritumumab receives U.S. orphan drug designation

Nov. 3, 2014

Kurume University discloses new cancer antigen peptide vaccines

Oct. 29, 2014

Biothera announces phase Ib trial of mucin-1-targeted antibody BTH-1704 and Imprime PGG

Oct. 28, 2014

Medivation licenses anti-PD-1 antibody pidilizumab from CureTech

Oct. 24, 2014

EMA grants orphan drug designation to isactuzumab govitecan

Oct. 21, 2014

Nivolumab and ipilimumab combination receives FDA orphan drug designation

Oct. 16, 2014

Advaxis reports preliminary data from phase I/II trial of ADXS-HPV in anal cancer

Oct. 16, 2014

Phase I data for MPDL-3280A for the treatment of UBC and other malignancies

Oct. 15, 2014

GAPVAC consortium advances a personalized cancer vaccine approach into the clinic for glioblastoma

Oct. 15, 2014

FDA accepts BLA for blinatumomab in acute lymphoblastic leukemia

Oct. 10, 2014

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...